| BUSINESSWEEK ONLINE : JULY 12, 1999 ISSUE | ||||||||
| ||||||||
 | ||||||||
| COVER STORY
Growing Arteries One of the most exciting frontiers in gene therapy is in the treatment of heart disease. Dr. Ronald G. Crystal of Cornell University's Weill Medical College in New York is one of several researchers who have devised an alternative to bypass surgery or angioplasty. Crystal's version of the therapy uses an engineered adenovirus with a gene that promotes blood-vessel growth. When the virus is injected into a patient near blocked coronary arteries, it can trigger the growth of new arteries--a kind of ''bio-bypass'' around the clogged vessels. Early results are encouraging, but it will be at least two years before tests are completed, Crystal said. The trials are being run by GenVec Inc. of Rockville, Md., with Parke-Davis Pharmaceutical Research, a division of Warner-Lambert Co. _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ |
|  |
 | |
 RELATED ITEMS Gene Therapy: One Family's Story COVER IMAGE: Gene Therapy GRAPHIC: Fixing a Gene TABLE: The Gene Therapist's Toolbox TABLE: Genetic Haves and Have-Nots? Growing Arteries On the Cutting Edge Gene-Therapy Companies Catch Their Breath TABLE: Who's Fighting What ONLINE ORIGINAL: This Fund Makes Biotech Bets a Bit Less Risky INTERACT E-Mail to Business Week Online | |||
